Table 1.
Baseline characteristics of recurrent/newly diagnosed glioblastoma patients
| Recurrent and newly diagnosed | Newly diagnosed | |
|---|---|---|
| N = 19 | N = 16 | |
| Gender | ||
| Male, N ( %) | 15 (78.9) | 12 (75.0) |
| Age in years | ||
| Mean (SD) | 51.8 | 55.3 (10.7) |
| Median | 52 | 54.5 |
| Range | 26–79 | 34–79 |
| Karnofsky statusa | ||
| Mean (SD) | 87 (9) | 87 (10.1) |
| Median | 90 | 90 |
| Range | 60–100 | 60–100 |
| HLA status, N (%) | ||
| A1+ | 6 | 5 |
| A2+ | 12 | 10 |
| A1+/A2+ | 1 | 1 |
| Prior therapy, N (%) | ||
| Surgery | 19 | 16 |
| Radiotherapy | 19 | 16 |
| Temozolomide | 19 | 16 |
| Avastin | 2 | |
| Gliadel | 4 | 2 |
| Extent of surgery, N (%) | ||
| Sub-total resection | 4 | 4 |
| Complete resection | 15 | 12 |
| First surgery to vaccine time (months) | ||
| Mean (SD) | 7.32 (5.69) | 5.49 (2.52) |
| Median | 5.19 | 4.52 |
| Range | 2.96–23.01 | 2.96–12.39 |
| Corticosteroid therapy (%) | 26.3 | 18.7 |
aScore collected at screening